Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas

Ashutosh Rai¹, Liza Das¹, Kanchan K. Mukherjee², Sivashanmugam Dhandapani², Manjul Tripathi², Chirag Kamal Ahuja³, Bishan Dass Radotra⁴ and Pinaki Dutta¹

¹ Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India,
² Department of Neurosurgery, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India,
³ Department of Radiodiagnosis, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India,
⁴ Department of Histopathology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

Purpose: Non-functioning pituitary adenomas (NFPAs) exhibit high recurrence rates after surgery. However, the determinants of recurrence are inconsistent in the available literature. The present study sought to investigate the association between nuclear phosphorylated EGFR (pEGFR) levels and recurrence of NFPAs.

Methods: Tissue microarrays from patients undergoing adenomectomy for NFPAs at our tertiary care center from 2003 to 2015 and having a minimum of 60 months of follow-up (n=102) were accessed. Immunohistochemical analysis (IHC) was performed to determine the expression of nuclear pEGFR T693. h-score was calculated as the product of staining intensity and the number of positively staining cells. Radiological surveillance (MRI) was performed to categorize NFPAs as recurrent or non-recurrent on follow-up.

Results: The mean age of the cohort was 50 ± 11 years with a male preponderance (61.1%). Recurrence was observed in 46.1% of the patients at a median of 123 months (IQR 72-159) of follow-up. pEGFR T693 positivity was higher in a significantly greater number of recurrent NFPAs as compared to non-recurrent NFPAs (95.7% vs 81%, p=0.02). h-scores were also significantly higher in recurrent NFPAs (122.1 ± 6 vs 81.54 ± 3.3, p<0.0001), pEGFR T693 positivity significantly predicted recurrence in NFPAs (HR=4.9, CI 2.8-8.8, p<0.0001). ROC analysis revealed an h-score cutoff of 89.8 as being associated significantly with recurrence (sensitivity 80%, specificity 78%, AUC 0.84, p<0.0001).

Conclusion: pEGFR T693 was expressed in significantly higher number of recurrent NFPAs. The h-scores were also higher in recurrent NFPAs. Nuclear pEGFR T693 may serve as a predictor of recurrence in NFPAs.

Keywords: pEGFR T693, non-functioning pituitary adenomas, recurrence, biomarker, prognosis
INTRODUCTION

Pituitary adenomas are the third most frequently diagnosed intracranial tumors, accounting for approximately 10–25% of all primary cranial neoplasms (1). The majority of pituitary adenomas exhibit aggressive behavior characterized by rapid cell growth, despite their benign nature. Non-functioning pituitary adenomas (NFPAs) account for 30% of pituitary tumors (2, 3). Although surgery is the primary therapeutic modality, NFPAs frequently have supra- or parasellar extension, owing to which total resection of the tumor is often not possible. Residual tumor regrowth has been reported in as high as 12–64% of patients over a duration of 5 to 15 years (4, 5). True recurrence, in patients with no visible tumor remnant post-surgery, has also been noted in nearly 16% of patients (5). These lines of evidence point towards the unmet knowledge gap in the determinants of recurrence, other than radiological parameters, for NFPAs. Further, the lack of circulating biomarkers and complex tumor pathology of NFPAs act as barriers in delineating the subset of patients at high risk of recurrence. Identification of good prognostic markers of recurrence can not only enable patient stratification for surveillance but also be exploited for their therapeutic potential.

Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein belonging to the HER family of receptor tyrosine kinases, which promotes multiple signaling cascades for cellular survival, such as RAS/MAPK, PI3K/Akt, Stat, and Src (6). While overexpression of cytoplasmic EGFR (EGFR-C) has been extensively studied as an important molecular target in oncology (7, 8), there have been recent reports stating the importance of nuclear EGFR (EGFR-N) from a similar perspective. EGFR-N regulates target genes involved in cell proliferation and angiogenesis with definite prognostic significance in terms of tumor progression and worse overall survival, especially in breast, ovarian, and lung cancers (9–13). Nuclear EGFR may act as a transcription factor, directly induce phosphorylation of proliferating cell nuclear antigen phosphorylation and confer resistance to radiotherapy (14–17). EGFR activation, resulting in either from mutation or ligand/receptor overexpression, is therefore associated with a variety of human cancers (18).

In the pituitary, EGFR acts as a cell growth factor and also directly induces prolactin synthesis (19). Both neoplastic and normal pituitary tissues express EGFR and phosphorylated EGFR [pEGFR] and overall, NFPAs have higher EGFR, pEGFR expression than functional adenomas. Protein phosphorylation is an important post-translational modification characterized by the addition of phosphorus groups to serine, threonine, or tyrosine residues catalyzed by kinase enzymes, resulting in altered protein functions. Characterization of phosphoproteins has directly aided the discovery of protein kinase inhibitors as therapeutic targets in oncology. In the context of the pituitary, the differential expression of phosphoproteins in tumors deserve investigation. Although approximately 60% of pituitary adenomas, including ACTH-secreting adenomas (40–80%) express EGFR (20–23), the role of the receptor in tumorigenesis remains under-investigated. There are a few reports suggesting high EGFR as a late event in pituitary tumorigenesis and as a marker of aggressiveness in a subset of tumors (21, 22). But the association with disease recurrence, especially in NFPAs, is not known. In our previous mass-spectrometry based study of global phosphoproteomics in NFPAs, we identified 2.6-fold hyperphosphorylation of EGFR at threonine 693 position (pEGFR T693) in recurrent NFPAs (24). The present study was aimed to validate the IHC expression of pEGFR T693 in a large monocentric cohort of NFPAs and correlate with clinical outcomes including recurrence during follow-up.

MATERIALS AND METHODS

Subjects

Over this period (2003–2015), there were a total of 1011 patients with NFPAs managed at the multidisciplinary pituitary clinic, PGIMER, Chandigarh. Of these, patients who underwent adenomectomy by the microscopic trans-sphenoidal route (TSS) and had a minimum of at least 60 months of follow-up (n=102) were included in the study. Tissue microarray (TMA) was constructed using these NFFA samples obtained from archived samples/blocks at the institute. The specimens were classified into two groups, namely recurrent and non-recurrent, based on radiological surveillance of the patients following TSS. Patients were followed-up post-surgery Controls used were normal pituitary glands obtained from autopsy samples within 3 hours of death (n=5). Both NFPAs and control samples were embedded in paraffin wax to make archival blocks for TMA. The study was approved by the Institute Ethics Committee PGIMER (NK/1790/PhD/6957). Before enrollment, written informed consent was obtained from all patients. All procedures performed in studies involving human participants were in accordance with the Helsinki declaration or comparable ethical standards.

All the cases met the following criteria: i) each paraffin block contained a sufficiently sized specimen to enable the construction of TMAs; ii) no radiation therapy was administered before surgery; iii) complete clinical information, including the endocrinological evaluation and imaging data, was available for a minimum of 60 months.

Immunohistochemical Analysis (IHC)

The tumor content and quality of all TMA slides were evaluated with hematoxylin and eosin (H&E) staining. NFPAs were classified as the following: gonadotropinomas, silent adenomas or null cell adenomas. Null cell adenomas were defined if they were negative for all 6 anterior pituitary hormones and all 3 transcription factors (Pit1, SF1, T-Pit). Primary antibody for pEGFR T693 (1:50, cat. no. ab75980, Abcam, UK) and EGFR (1:100, ab52894Abcam, UK) were used. Slides were scored for staining positivity (number of cells) and intensity of nuclear pEGFR T693. The intensity of staining for pEGFR T693 was scored as follows: 0, no; 1, weak; 2, moderate, and 3, high intensity (25). The number and distribution of positively stained cells were scored on a scale of 0–100%. A composite
Demographic and clinicopathological parameters of the cohort are summarized in Table 1. The mean age of the cohort was 50 ± 11.0 years (range 24-75 years) at presentation with a male preponderance (males 63.7% vs females 36.3%). All patients had macroadenomas with a median tumor volume of 14000mm³. There were 47 giant adenomas. Recurrence was noted in 46% of patients at a median duration of 123 months (range 60-213months) of follow-up. IHC showed a positive nuclear pEGFR T693 expression in 88% (90/102) of the specimens. Of the 90 positive specimens, 50 showed weak staining, 37 moderate, and 3 high-intensity staining.

**Age and Gender**  
Patients were grouped into three age classes: younger than 30 years (I), 30-50 years (II), and older than 50 years (III). The rates of recurrence were not significantly different between the 3 groups (45% vs 46% vs 45%, p=0.85). In group I (n=11), 7 patients showed positive nuclear pEGFR T693 expression with a mean h-score of 82.2 ± 17.1 (range 7.0-201.1). In group II (n=69), 62 patients showed positive IHC with a mean h-score of 94.3 ± 17.1 (range 11.5 to 227.4). In group III (n=22), 21 patients showed positive IHC with a mean h-score of 94.0 ± 7.0 (range 41.8-166.6). However, there was no significant difference between h-scores of different age groups (p=0.67) (Supplementary Figure 2A). The mean h-scores of age group II (p=0.0001) and III (p=0.0005) showed a significant difference between recurrent and non-recurrent tumors.

Male preponderance was noted in both recurrent and non-recurrent groups (65.9% vs 63.6%, p = 0.51). Overall, 86.2% (56/65) of the tumors of male patients and 91% (34/37) of the women were positive for pEGFR T693. Among male patients, 47.6% tumors (n=31) were weakly positive, 36.9% (n=24) moderate, and 1.5% (n=1) strongly positive. In females, pEGFR T693 staining scores classified 52.7% (n=19) as weakly positive, 33.3% (n=12) as moderate and 5.5% (n=2) as strongly positive. There was no significant difference between mean h-scores of males and females (93.1 ± 5.0 vs 93.9 ± 7.5, p=0.99). (Supplementary Figure 2B).

**Tumor Subtypes**  
Patients were classified based on the tumor subtype as gonadotropinomas, null cell adenomas, or silent adenomas. The recurrence rate was 71.4%, 38.8, and 44.4% in silent adenomas, gonadotropinomas, and null cell adenomas respectively. The majority of the gonadotropinomas (88.9%) (39 were weak, 23 moderate and 2 were strong positive) showed positive staining (mean h-score 91.8 ± 4.8) while 77% null cell adenomas (5 weak, 2 moderate positive) showed positive staining (mean h-score 73.6 ± 14.3) for pEGFR T693. Among silent adenomas, 90% showed (19/21) positive staining with a mean h-score of 105.1 ± 9.0. There was no significant difference in h-scores between the groups (p=0.157) (Supplementary Figure 2C).

**Tumor Grade**  
High Ki67 (>3%) was found in similar proportion of patients in both recurrent and non-recurrent groups (19.1% vs 18.2%, p=0.91). NFPAs were classified based on the proposed clinicopathological classification by Trouillas et al. Eighty-four
TABLE 1 | Baseline clinical, radiological and histopathological characteristics of the cohort with composite h-scores stratified on the basis of demographic characteristics.

| Parameter                     | pEGFR T693 h-score | p-value |
|-------------------------------|--------------------|---------|
|                               | Range (Min-Max)    | Mean ± SD |
| Age                           |                    |         |
| <30 years (n=11)              | 7.05-201.1         | 82.2 ± 17.1 | 0.67 |
| 30-50 years (n=69)            | 11.5-227.4         | 94.3 ± 17.1 |
| >50 years (n=22)              | 41.8-166.6         | 94.0 ± 7.0  |
| Gender                        |                    |         |
| Female (n=37)                 | 13.8-227.4         | 93.9 ± 7.5 | 0.99 |
| Male (n=65)                   | 7.0-209.3          | 93.1 ± 5.0  |
| Tumor diameter                |                    |         |
| Giant (n=47)                  | 7.0-227.4          | 90.7 ± 6.9 | 0.57 |
| Macro (n=55)                  | 11.5-209.3         | 95.6 ± 5.0  |
| Tumor volume                  |                    |         |
| Above median (14000 mm³)      | 7.0-209.3          | 92.3 ± 5.3  |
| Below median (14000 mm³)      | 11.5-227.4         | 92.3 ± 6.6  |
| Tumor extension               |                    |         |
| Intrasellar (n=30)            | 49.9-209.3         | 93.6 ± 7.3 | 0.47 |
| SSE+PSE (n=16)                | 11.5-201.1         | 86.3 ± 5.7  |
| SSE+PSE+ISE (n=6)             | 7.0-227.4          | 119.3 ± 30.8 |
| SSE+ISE (n=4)                 | 64.4-158.2         | 94.7 ± 21.7 |
| Clinico-pathological grading by Trouillas et al | | |
| 1a (n=44)                     | 11.5-201.1         | 81.8 ± 5.8 | 0.05 |
| 1b (n=7)                      | 101-158            | 130.7 ± 9.2 |
| 2a (n=43)                     | 7.0-227.4          | 95.6 ± 6.2  |
| 2b (n=8)                      | 13.8-178.8         | 128.4 ± 10.7 |
| 1a+2a (n=87)                  | 7.0-227.4          | 89.1 ± 4.3  |
| 1b+2b (n=15)                  | 13.8-178.8         | 116.2 ± 11.0 |
| IHC                           |                    |         |
| Silent Adenomas (n=21)        | 32.7-201.1         | 105.1 ± 9.0 | 0.15 |
| Gonadotropinomas (n=72)       | 13.8-227.4         | 91.1 ± 4.8  |
| Null Cell adenomas (n=9)      | 7.0-141            | 73.6 ± 14.3 |
| Recurrence                    |                    |         |
| Recurrent (n=47)              | 34.6-227.4         | 117 ± 6.0  |
| Non-recurrent (n=65)          | 7.0-144.4          | 71.2 ± 3.7  |

Data are presented as range or mean ± SD.

SSS, suprasellar extension; PSE, parasellar extension; ISE, infrasellar extension; IHC, immunohistochemistry.

*significant, ****highly significant.

The bold values refer to significant parameters.

percent of tumors (n=37) with grade 1a (non-invasive, non-proliferative) were positive for pEGFR with a mean h-score of 81.8 ± 5.8 (range 11.5-201). There were 27 weakly positive, 9 moderate, and 1 strongly positive tumor. All grade 1b (non-invasive, proliferative) tumors (n=7) were positive for nuclear pEGFR with a mean h-score of 130.7 ± 9.2 (range 101-158). Ninety % (39/43) of grade 2a (invasive, non-proliferative) tumors were positive for nuclear pEGFR with a mean h-score of 95.6 ± 6.2 (range 7.0-227.4). All patients with grade 2b (invasive, proliferative) NFPAs were positive with a mean h-score of 128.4 ± 10.7 (range 13.8-178.8), one was weak positive while five were moderate positive. There was no significant difference between the mean h-scores across the tumor grades (p=0.05) (Supplementary Figure 2D). Proliferative tumors (1b+2b) had significantly higher mean h-scores than non-proliferative (1a+2a) (p=0.02) (Supplementary Figure 2E).

Recurrence

Positive pEGFR IHC was found in a significantly more number of subjects with recurrent than non-recurrent tumors (95.7% vs 81%, p=0.02). In the 55 non-recurrent cases, 81% (n=45) were positive for pEGFR with 7 demonstrating moderate and 38 low positive staining. Among the 47 recurrent NFPAs, 95.7% (n=45) were positive for pEGFR T693 with 3 showing strong, 30 moderate, and 12 low positive staining (Figure 1). Further analysis was performed using clinically relevant staining intensity of nuclear pEGFR T693, defined as moderate or strong staining. This showed a significantly greater proportion of patients in the recurrent NFPA group (Figure 1) than the non-recurrent group (73.3 vs 15.6%, p<0.0001). Non-specific antibody binding was excluded by using positive controls (breast cancer (Figure 1C), cervical cancer (Figure 1F), and omission of primary antibody in the above-mentioned tissue was used as negative control (Figure 1)). Normal pituitary controls obtained from autopsy samples were also found to be negative for pEGFR T693 immunostaining (Figure 1L). The hyperphosphorylation of pEGFR T693 in recurrent NFPAs was also confirmed by Western blot (Figure 1M). Recurrent NFPAs also had significantly higher h-scores than non-recurrent tumors (117 ± 6.0 vs 71.2 ± 3.7, p<0.0001) (Figure 1N). The nuclear positivity of pEGFR T693 was confirmed by immunofluorescence in these tumors (Figures 2A–C and using HeLa cell lines as positive control, Figures 2G–I). Total EGFR showed membranous positivity in Hela cells (positive control) (Figure 2J–L) while no
FIGURE 1 | Overexpression of pEGFR T693 in recurrent NFPAs. Immunohistochemistry of pEGFR T693 showed overexpression in recurrent NFPAs (B, E, H, K) as compared to non-recurrent NFPAs (A, D, G, J). pEGFR T693 showed strong nuclear positivity (brown) marked by black arrows. Breast cancer (C) and cervical cancer (F) were used as the positive controls. No staining was observed in the negative control (I) and normal pituitary (L). Western blots of representative tumor samples are depicted in (M). The h-score (product of the number of cells with positive staining and staining intensity) showed statistically significant overexpression of pEGFR T693 in recurrent NFPAs as compared to non-recurrent (p < 0.0001) (N). Quantification of the blots (O) show overexpression of pEGFR T693 in representative tumor samples of 18 recurrent NFPAs as compared to 18 non-recurrent ones. Magnification 400x. ****highly significant.
EGFR expression has been observed in NFPA (Figures 2D–F). Immunohistochemistry showed the absence of EGFR expression in 96% of NFPAs (Supplementary Figure 4). There was a significant correlation between the h-score of pEGFR T693 and the recurrence of NFPAs (r=0.554, p=0.000) (Table 2). Receiver operating curve (ROC) analysis for pEGFR h-scores used in differentiating recurrent from non-recurrent tumors revealed a cutoff of 89.8 as significantly predicting recurrence (Sensitivity 80%, specificity 78%, AUC 0.84, 95% CI 0.76-0.92, p < 0.0001) (Figure 3A).

Univariate analysis showed positive pEGFR T693 staining (p<0.0001) and tumor grade (p=0.02) to be significantly associated with recurrence, while other clinicopathological parameters were not associated with NFPAs recurrence (Table 1). A significant association between pEGFR T693 expression and recurrence (HR=4.9, CI 2.8-8.8, P<0.0001) was observed. The association of tumor grade as per the recently proposed clinicopathological classification (26) with recurrence of NFPAs in our study was 1.7 (CI-0.7-3.9, p=0.10).

**Recurrence-Free Survival Analysis**

During follow-up, 46% patients (n=47) experienced tumor recurrence. Patients were divided into two groups based on the h-score cut-off of 89.8 (Figure 3A). In the Kaplan-Meier survival curve comparing the 17-year overall recurrence-free survival, patients with h-score less than 89.8 had higher overall recurrence-free survival compared to the patients with higher h-score (p<0.0001) (Figure 3B).

**DISCUSSION**

The current study is the first, to the best of our knowledge, to investigate the association of phosphorylated EGFR (pEGFR T693) with the recurrence of NFPAs. We demonstrated that pEGFR T693 expression (both intensity and percentage of cells) was increased in the recurrent NFPAs compared with the non-recurrent NFPAs. We also found a greater risk conferred by pEGFR T693 for NFPA recurrence.
months, 46.1% of patients experienced tumor recurrence, proliferation). Further, at a median period of follow-up of 72 tumor grade (a composite measure of invasiveness and recurrence as compared to conventionally used parameters like tumor grade (a composite measure of invasiveness and proliferation). Further, at a median period of follow-up of 72 months, 46.1% of patients experienced tumor recurrence, significantly predicted by the identified cutoff of h-score (89.8) for pEGFR T693. These findings suggest the potential utility of nuclear pEGFR T693 in predicting recurrence in NFPAs. In association with tumor grade, pEGFR T693 can possibly be used for identifying the subset of patients with a high risk of recurrence, to improve their surveillance frequency, and initiate early management in case of clinically significant tumor recurrence.

NFPAs are characterized by lower rates of remission than functioning pituitary adenomas (27). Recurrence or regrowth of residual tumor has been observed in up to 15 to 66% of patients treated with surgery alone and up to 28% with the use of adjuvant radiotherapy over a median follow-up duration of 5.9 years (28). Even when patients with clinically significant recurrence requiring re-intervention are considered, the rates are as high as 20% (29). The higher recurrence rate of NFPAs compared to pituitary tumors overall suggests that multiple factors may be responsible for this biological behavior and not tumor size alone. There is also a rare but existing risk of carcinomatous transformation in patients with recurrent and/or invasive NFPAs (30). While functional pituitary adenomas can be easily followed up for recurrence using biomarkers, there is no similar parameter to predict recurrence in NFPAs, thereby delaying early recognition and timely management.

Factors predicting recurrence in NFPAs have not been proven conclusively. In a meta-analysis, clinical parameters like age, gender, tumor size, invasion, and proliferation were found to be significant in some studies but not in others (27, 31, 32). In more recent studies, the Trouillas classification of tumor grading based on invasion and proliferation was found to predict recurrence with the highest-grade lesions (2b invasive and proliferative) harboring an almost 9 times higher risk of recurrence than the lowest grade lesions (1a invasive) (33). In other reports, MRI texture analysis parameters enabled the prediction of recurrence even after adjusting for other factors like age, Ki67, and completeness of resection (34). The tumor subtype has been reported to be associated with higher recurrence in some studies but not in others (35–37). Overall, there exist a lacuna inaccurate predictive factors that could help stratify patients based on low or high risk of recurrence or progression. In the context of a notably high rate of recurrence and lack of suitable biomarkers of hypersecretion to identify recurrence, this remains enigmatic.

Microarray analysis studies are limited in the context of recurrence prediction of NFPAs. In a small study, circulating RNAs, especially the circ RNA 102597 was found to predict recurrence using these assays in conjunction with other described factors including Ki67 (38, 39). β-catenin has been found to predict recurrence in another study (40). Protein phosphorylation, one of the most important post-translational modification processes, enables enrichment of protein diversity. The total number of proteoforms significantly exceeds the number of transcripts and genes in normal individuals in the hierarchy of omics, it is ultimately the proteomics of a cell that decides its functions and fate. Hence, evidence on phosphoproteomics, though less well characterized, holds the promise of being able to clarify the still elusive molecular mechanisms involved in the genesis and progression of NFPAs. Hence, it can be contemplated that phosphorylation-mediated cellular events that occur as part of post-translational

| Parameter                | Pearson’s r | p value |
|--------------------------|-------------|---------|
| Age                      | 0.04        | 0.66    |
| Gender                   | 0.001       | 0.99    |
| Tumor Diameter           | 0.05        | 0.57    |
| Tumor Volume             | 0.001       | 0.99    |
| Tumor Extension          | 0.089       | 0.37    |
| Clinico-pathological grading by Trouillas et al. | 0.225 | 0.03* |
| Immunohistochemistry     | -0.194      | 0.05    |
| Recurrence               | 0.554       | 0****   |

*significant ****highly significant. The bold values refer to significant parameters.
modification of proteins have a putative role in regrowth of remnant tumor or recurrence in case of no discernible residue post-surgery. In line with this postulation, there is some evidence to suggest that phosphorylated AMPK/ATF2 is involved in tumorigenesis in GH secreting pituitary adenomas (41). However, knowledge about phosphoproteome profiles of NFPAs is limited (42). In the context of NFPAs, the pursuit of biomarkers that enable the prediction of recurrence and can be employed as potential drug targets is certainly encouraging in the current era of personalized medicine.

EGFR plays an important role in the progression of many types of cancer by activation of mitogenic pathways, altering cell cycle progression, and by downregulating tumor suppressor genes. Nearly two decades ago, two independent reports documented nuclear EGFR status in bladder and cervical cancers using IHC. While these early studies were the first to quantify nuclear EGFR in patient tumors, they did not examine the prognostic value of nuclear EGFR expression. The Thr 693 phosphorylation of EGFR by p38 leads to its internalization. Internalized EGFR can form signaling complexes in endosomes, which may trigger different signals than the membrane-localized receptor (43). The nuclear counterpart of EGFR appears to be the full-length receptor and likely, in the phosphorylated form, as shown by many studies. In other studies, EGFR/ERK signaling pathway has been found to mediate cell migration, invasion, and proliferation (44).

Among pituitary adenomas, EGFR has been reasonably well studied in corticotropinomas, where IHC positivity in nearly 55% of tumors has been documented (45). Further, the degree of expression in these tumors was found to be much greater than normal pituitary samples and it was also found to be correlated with tumor burden in terms of ACTH and cortisol. In that study, pEGFR was found to be significantly associated with tumor recurrence but there was no association with age, gender or duration of symptoms, or tumor size suggesting the utility of EGFR as a biomarker for predicting recurrence. However, the study was silent regarding the exact site of the phosphorylation. Further, in corticotropinomas, EGFR overexpression is a consequence of 14-3-3 USP8 mutations, which are, in fact, quite specific to this tumor subtype. Thus, the pEGFR found in NFPAs, with the unique phosphorylation site at Thr 693, maybe a distinctive step in the molecular pathogenesis of NFPAs that determines their recurrence. Further, available evidence suggests almost a three-fold higher pEGFR expression in NFPAs than functional adenomas (21). EGFR has been identified as a transcriptional co-activator for several cancer-promoting genes, including cyclin D1, nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) (46, 47). Cyclin D1 has a bearing on cell proliferation, recurrence, and aggressive behavior of pituitary tumors (48). Overexpression of cyclin D1 in NFPAs maybe secondary to the molecular aberration of nuclear translocation of EGFR due to phosphorylation at Thr 693 site.

The translational benefit offered by the current study can be extended to future studies using targeted therapy (pEGFR 693 antagonist) both in-vitro and in clinical settings to restrain the growth and recurrence of NFPAs. Results from the current study implicate nuclear EGFR in the etiology of recurrent NFPAs and patients with IHC positive for pEGFR T693 should be followed up more closely. This specific marker holds the dual advantage of predicting recurrence as well as being targeted for therapy. It is expected to be of maximum benefit in tumors with a high expression of this receptor. Usage of drugs like gefitinib and erlotinib for aggressive ACTH producing pituitary adenomas (49) and recently, lapatinib for aggressive prolactinomas (50) has produced encouraging results, but similar therapies have not hitherto been attempted in recurrent NFPAs. Further, assessment of synergistic efficacy of this treatment modality in conjunction with radiotherapy could also be a potent therapeutic modality for patients with NFPAs, which warrants investigation in future studies.

CONCLUSION

The current study provides evidence that nuclear pEGFR T693 expression is significantly higher in recurrent than non-recurrent NFPAs. Prediction of recurrence was higher with phosphorylated EGFR than tumor grade and there was no association with baseline tumor size. pEGFR T693 is a potential biomarker to predict recurrence in NFPAs.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Institute Ethics Committee, PGIMER, Chandigarh, India. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

All authors contributed equally to the study and have read and approved the final version of the manuscript.

FUNDING

We thank the Department of Biotechnology, Government of India for research support [6242-P109/RGCB/PMD/DBT/KNMI/2015] to the PGIMER. We thank the Council of Scientific and Industrial Research, University Grants Commission, and the Government of India for financial support. AR is a recipient of a Senior Research Fellowship from the Council of Scientific and Industrial Research/University Grants Commission, Government of India.
ACKNOWLEDGMENTS

We acknowledge the expert guidance of our mentor, the late Professor K.K.M., Professor of Neurosurgery, to whom this paper is dedicated. He may be no more with us physically, but his legacy lives on.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2021.708111/full#supplementary-material

Supplementary Figure 1 | Flow diagram of NFPAs recruited in the study.

Supplementary Figure 2 | pEGFR T693 overexpressed in proliferative NFPAs. Quantitative h-score of pEGFR T693 immunohistochemistry with clinical parameters (A–E) showed no differential expression across age (A), gender (B), immunohistochemistry of hormones (C), and Trouillas classification (D). Proliferative tumors as per Trouillas classification (1b + 2b) showed significantly higher expression of pEGFR T 693 as compared to non-proliferative NFPAs (1a+2a) (E). Age group (A): 1: < 30 years, 2: 30-50 years, 3: >50 years. SA, silent adenoma; GN, gonadotropinoma; NC, null cell adenoma.

Supplementary Figure 3 | NFPAs quantitative h-score of pEGFR T693 immunohistochemistry with tumor size and extension (A–E) showed no differential expression across tumor diameter (A), tumor volume (B), suprasellar extension (C), parassellar extension (D), and infrasellar extension (E). The Student’s t-test was used for comparing the groups. SSE-suprasellar extension, PSE-parassellar extension, ISE-infrasellar extension.

Supplementary Figure 4 | EGFR expression in NFPAs (n=50). Positive EGFR expression was observed in two patients (D) and while others were negative (E). Cervical carcinoma was used as the positive control (A) while there was no expression of EGFR in normal pituitary (n=5), Cushing’s (n=10), and negative control. Magnification 400x.

REFERENCES

1. Chen Y, Wang CD, Su ZP, Chen YX, Cai L, Zhuge QC, et al. Natural History of Postoperative Nonfunctioning Pituitary Adenomas: A Systematic Review and Meta-Analysis. Neuroendocrinology (2012) 96(4):333–42. doi: 10.1159/000339823
2. Aghi MK, Chen CC, Fleseriu M, Newman SA, Lucas JW, Kuo JS, et al. Congest of Neurosurgical Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Patients With Nonfunctioning Pituitary Adenomas: Executive Summary. Neurosurgery (2016) 79(4):521–3. doi: 10.1227/NEU.000000000001386
3. Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S, et al. Management of Clinically Non-Functioning Pituitary Adenoma. Nat Rev Endocrinol (Paris) (2015) 76(3):239–47. doi: 10.1016/j.nrendo.2015.04.002
4. Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C, et al. Factors Predicting Relapse of Nonfunctioning Pituitary Macroadenomas After Neurosurgery: A Study of 142 Patients. Eur J Endocrinol (2010) 163(2):193–200. doi: 10.1530/EJE-10-0255
5. Wei P, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers (Basel) (2017) 9(5):52. doi: 10.3390/cancers9050052
6. Navolanic PM, Steelman LS, McCubrey JA. EGF Family Signaling and Its Association With Breast Cancer Development and Resistance to Chemotherapy. J Int J Oncol (2003) 22(2):237–52. doi: 10.3892/ijo.22.2.237
7. Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, et al. Nuclear expression of EGFR in normal pituitary (n=5), Cushing’s (n=10), and negative control. Magnification 400x.
8. Lo HW, Huo SC, Ali-Sayed M, Gunduz M, Xia W, Wei Y, et al. Nuclear Interaction of EGFR and STAT3 in the Activation of the INOS/NO Pathway. Cancer Cell (2005) 7(6):575–89. doi: 10.1016/j.ccr.2005.05.007
9. Lo HW, Ali-Sayed M, Wu Y, Bartholomew GS, Hsu SC, Hung MC. Nuclear-Cyttoplasmic Transport of EGF Involves Receptor Endocytosis, Importin Beta1, and CRM1. J Cell Biochem (2006) 98(6):1570–83. doi: 10.1002/jcb.20786
10. Hadzisijedic I, Mustac E, Jonjic N, Petkovic N, Haliloglu OA, Tanriover N, et al. Epidermal growth factor (EGF) as a molecular target in cancer. Frontiers in Endocrinology (2018) 17:812. doi: 10.3389/fendo.2018.01781
11. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, et al. Nuclear EGF Receptor Expression Predicts Poor Survival in Early Stage Non-Small Cell Lung Cancer. Oncol Letters. (2019) 17(2):1531–8. doi: 10.3892/ol.2018.9756
12. Herbst RS. Review of Epidermal Growth Factor Receptor Biology. Int J Radiat Oncol Biol Phys (2004) 59(2 Suppl):21–6. doi: 10.1016/j.ijrobp.2003.11.041
13. Murdoch GH, Potter E, Nicolaisen AK, Evans RM, Rosenfeld MG. Epidermal Growth Factor Rapidly Stimulates Prolactin Gene Transcription. Nature (1982) 300(5888):192–4. doi: 10.1038/300192a0
14. Fukuoka H, Cooper O, Mizutani J, Tong Y, Ren SG, Bannykh S, et al. HER2/erbB2 Receptor Signaling in Rat and Human Prolactinoma Cells: Strategy for Targeted Prolactinoma Therapy. Mol Endocrinol (2011) 25(1):92–103. doi: 10.1210/me.2010-0353
15. 19. Murdoch GH, Potter E, Nicolaisen AK, Evans RM, Rosenfeld MG. Epidermal Growth Factor Rapidly Stimulates Prolactin Gene Transcription. Nature (1982) 300(5888):192–4. doi: 10.1038/300192a0
27. Roelfsema F, Biermasz NR, Pereira AM. Clinical Factors Involved in the Recurrence of Pituitary Adenomas After Surgical Remission: A Structured Review and Meta-Analysis. *Pituitary* (2012) 15(1):71–83. doi: 10.1007/s11102-011-0347-7

28. Tampoulou M, Ntali G, Ahmed S, Arlt W, Ayuk J, Byrne JV, et al. Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK Centers. *J Clin Endocrinol Metab* (2017) 102(6):1889–97. doi: 10.1210/jc.2016-4061

29. Yavropoulou MP, Tsoli M, Barkas K, Kaltsas G, Grossman A. The Natural History and Treatment of Non-Functioning Pituitary Adenomas (Non-Functioning PitNETs). *Endocr Rel Cancer* (2020) 27(10):R375–90. doi: 10.1530/ERC-20-0136

30. Lenders N, McCormack A. Malignant Transformation in non-Functioning Pituitary Adenomas (Pituitary Carcinoma). *Pituitary* (2018) 21(2):217–29. doi: 10.1007/s11102-017-0857-z

31. Greenman Y, Ouaknine G, Veshchev I, Reider-Groswasser II, Segev Y, Stern MA, et al. Postoperative Surveillance of Clinically Nonfunctioning Pituitary Macroadenomas: Markers of Tumor Quiescence and Regrowth. *Clin Endocrinol* (2003) 58(6):763–9. doi: 10.1046/j.1365-2265.2003.01784.x

32. Lee MH, Lee JH, Seol HJ, Lee JJ, Kim JH, Kong DS, et al. Clinical Concerns About Recurrence of Non-Functioning Pituitary Adenoma. *Brain Tumor Res Treat* (2016) 4(1):1–7. doi: 10.14791/btbr.2016.4.1.1

33. Lelotte J, Mourin A, Fomekong E, Michotte A, Raftopoulos C, Maiter D. Both Invasiveness and Proliferation Criteria Predict Recurrence of Non-Functioning Pituitary Macroadenomas After Surgery: A Retrospective Analysis of a Monocentric Cohort of 120 Patients. *Eur J Endocrinol* (2018) 178(3):237–46. doi: 10.1530/EJE-17-0965

34. Galm BP, Martinez-Salazar EL, Swearingen B, Torrioni M, Klibanski A, Bredella MA, et al. MRI Texture Analysis as a Predictor of Tumor Recurrence or Progression in Patients With Clinically Non-Functioning Pituitary Adenomas. *Eur J Endocrinol* (2018) 179(3):191–8. doi: 10.1530/EJE-18-0291

35. Langlois F, Lim DS, Varlamov E, Yedinak CG, Cetas JS, McCartney S, et al. Clinical Profile of Silent Growth Hormone Pituitary Adenomas; Higher Recurrence Rate Compared to Silent Gonadotroph Pituitary Tumors, A Large Single Center Experience. *Endocrine* (2017) 58(3):528–34. doi: 10.1007/s12020-017-1447-6

36. Cho HY, Cho SW, Kim SW, Shin CS, Park KS, Kim SY. Silent Corticotroph Adenomas Have Unique Recurrence Characteristics Compared With Other Nonfunctioning Pituitary Adenomas. *Clin Endocrinol* (2010) 72(5):468–53. doi: 10.1111/j.1365-2265.2009.03673.x

37. Fountas A, Lavrentaki A, Subramanian A, Toulis KA, Niranathanakumar K, Karavitiaki N. Recurrence of Silent Corticotroph Adenomas After Primary Treatment: A Systematic Review and Meta-Analysis. *J Clin Endocrinol Metab* (2019) 104(4):1039–48. doi: 10.1210/clinem/dgaa805

38. Hu Y, Zhang N, Zhang S, Zhou P, Lv L, Richard SA, et al. Differential Circular RNA Expression Profiles of Invasive and Non-Invasive Non-Functioning Pituitary Adenomas: A Microarray Analysis. *Medicine* (2019) 98(26):e16148. doi: 10.1097/MD.00000000000016148

39. Guo J, Wang Z, Miao Y, Shen Y, Li M, Gong L, et al. A Two–circRNA Signature Predicts Tumor Recurrence in Clinical Non–Functioning Pituitary Adenoma. *Oncol Rep* (2019) 41(1):113–24. doi: 10.3892/or.2018.6851

40. Liu C, Wu Y, Yu S, Bai J, Li C, Wu D, et al. Increased β-Catenin and C-Myc Expression Predict Aggressive Growth of Non-Functioning Pituitary Adenomas: An Assessment Using a Tissue Microarray-Based Approach. *Mediat Inflamm* (2019) 2019:1–9. doi: 10.1155/2019/3791569

41. Zhao S, Feng J, Li C, Gao H, Lv P, Li J, et al. Phosphoproteome Profiling Revealed Abnormally Phosphorylated AMPK and ATF2 Involved in Glucose Metabolism and Tumorigenesis of GH-PAs. *J Endocrinol Invest* (2019) 42(2):137–48. doi: 10.1007/s40618-018-0890-4

42. Liu D, Li J, Li N, Lu M, Wen S, Zhan X. Integration of Quantitative Phosphoproteomics and Transcriptomics Revealed Phosphorylation-Mediated Molecular Events as Useful Tools for a Potential Patient Stratification and Personalized Treatment of Human Nonfunctional Pituitary Adenomas. *Eur J Endocrinol* (2020) 11(3):419–67. doi: 10.1530/ejea-20-00215-0

43. Visea AV, Lamaze C, Schmid SL. Control of EGFR Receptor Signaling by Clathrin-Mediated Endocytosis. *Science* (1996) 274(5295):2086–9. doi: 10.1126/science.274.5295.2086

44. Wang J, Zhang Z, Li R, Mao F, Sun W, Chen J, et al. ADAM12 Induces EMT and Promotes Cell Migration, Invasion and Proliferation in Pituitary Adenomas via EGFR/ERK Signaling Pathway. *Biomed Pharmacother* (2018) 97:1066–77. doi: 10.1016/j.biopha.2017.11.034

45. Liu X, Feng M, Dai C, Bao X, Deng K, Yao Y, et al. Expression of EGFR in Pituitary Corticotroph Adenomas and Its Relationship With Tumor Behavior. *Front Endocrinol* (2019) 101–6. doi: 10.3389/endo.2019.00785

46. Lo HW, Hung MC. Nuclear EGFR Signalling Network in Cancers: Linking EGFR Pathway to Cell Cycle Progression, Nitric Oxide Pathway and Patient Survival. *Br J Cancer* (2006) 92(184):8. doi: 10.1038/sj.bjc.6602941

47. Brand TM, Iida M, Li C, Wheeler DL. The Nuclear Epidermal Growth Factor Receptor Signaling Network and its Role in Cancer. *Disc Med* (2011) 12(66):419–32.

48. Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB. Cyclin D and Cyclin E Expression in Normal and Adenomatous Pituitary. *Eur J Endocrinol* (2000) 143(1):R1–6. doi: 10.1530/ej.0.143r001

49. Feelders RA, Newell-Price J, Piovello R, Nieman LK, Hofland LJ, Lacroix A. Advances in the Medical Treatment of Cushing’s Syndrome. *Lancet Diabetes Endocrinol* (2019) 7(4):300–12. doi: 10.1016/S2213-8587(18)30155-4

50. Cooper O, Bonert VS, Rudnick J, Pressman BD, Lo J, Salvatori R, et al. EGFR/ ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. *J Clin Endocrinol Metab* (2021) 106(2):e917–25. doi: 10.1210/clinem/dgaa805

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.